The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process
Share this article
Click the icon of the social media platform on which you would like to share this article.
Email this article to a friend
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Other content recommended for you
- Value assessment frameworks: who is valuing the care in healthcare?
- Audit of data redaction practices in NICE technology appraisals from 1999 to 2019
- National Institute for Health and Clinical Excellence appraisal and ageism
- Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting
- NICE is dead; long live NICE
- NICE and neurology
- Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006
- Justice and the NICE approach
- Diagnosis and management of the epilepsies in children: a summary of the partial update of the 2012 NICE epilepsy guideline
- Cost-effectiveness of exercise referral schemes enhanced by self-management strategies to battle sedentary behaviour in older adults: protocol for an economic evaluation alongside the SITLESS three-armed pragmatic randomised controlled trial